Is the use of secukinumab after anti-TNF therapy greater than expected for the risk of developing inflammatory bowel disease? Fatih Albayrak, Mustafa Gür, Ahmet Karataş, Süleyman Serdar Koca, Bünyamin Kısacık

A cost-consequence analysis of the preferential use of secukinumab versus adalimumab for the treatment of psoriatic arthritis Alberto Jiménez-Morales, Rafael Cáliz, Susana Aceituno, Miriam Prades, Carles Blanch

ASDAS high disease activity versus BASDAI elevation in patients with ankylosing spondylitis as selection criterion for anti-TNF therapy Nathan Vastesaeger, Bert Vander Cruyssen, Juan Mulero, Jordi Gratacós Masmitjá, Pedro Zarco, Raquel Almodovar, Pilar Font, Xavier Juanola, Eduardo Collantes-Estevez